News

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data

09.09.20131672

Cangrelor is a potent, rapid-acting, reversible intravenous platelet inhibitor that was tested for percutaneous coronary intervention (PCI) in three large, double-blind, randomised trials.

Russian Society of Cardiology was properly represented at the European Congress of Cardiology in Amsterdam

07.09.20133183

Impact of obesity on response to thienopyridine and bleeding risk in patients treated after acute coronary syndrome by clopidogrel or prasugrel

06.09.20131772

Variability of response to thienopyridine has been described for both clopidogrel and prasugrel.

Reduced kidney function and anemia as risk factors for new onset AF

05.09.20131876

Each of chronic kidney disease (CKD) and anemia is a potential independent risk factor for cardiovascular disease (CVD); however, reduced kidney function, anemia, and its relationship have not been fully evaluated for the incidence of atrial fibrillation (AF).

Gender Data Forum: Are DES Safer and More Effective Than Bare Metal Stents in Women?

04.09.20131588

The use of drug-eluting stents (DES) in women is more effective and safe than using bare-metal stents during long-term follow-up, according to a study released on Sept. 2 during the ESC Congress 2013 and simultaneously published in The Lancet.

2013 ESC Gold Medal award winners

03.09.20132636

Two ESC gold medallists for 2013: Evgeny Chazov and Douglas Zipes receive ESC honours.

RAFT: Beta Blocker Therapy in Congestive Heart Failure Patients With LVEF

03.09.20131820

Use of beta blocker therapy to treat congestive heart failure (CHF) patients with reduced left ventricular ejection fraction (LVEF) remains paramount, with benefits independent of those of newer CHF therapies, according to results of the RAFT Study presented on Sept. 2 during the ESC Congress 2013.